Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden.
Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden.
复制标题
DOI：
10.1007/s00262-023-03397-4
复制
发表时间：
2023-07
影响因子：
5.8
通讯作者：
Jatoi, Aminah
中科院分区：
文献类型：
--
作者：
Storandt, Michael H.;Tran, Nguyen;Martin, Nichole;Jatoi, Aminah
培溴利珠单抗对胰腺癌患者的益处微乎其微。我们在早期使用Pembrolizumab的亚组中探讨了存活率和患者治疗负担(例如，治疗后14天内死亡)。这项多点研究检查了从2004年到2022年连续接受胰腺/培溴利珠单抗治疗的患者。中位总生存期4个月被认为是有利的。患者的治疗负担和病历引用是描述性的。纳入41例患者(中位年龄66岁，范围：36-84岁)。15人(37%)患有dMMR、MSI-H、TMB-H或Lynch综合征；23人(56%)同时接受治疗。中位生存期为7.2个月(95%可信区间为5.2、12.7个月)，死亡29例。患有dMMR、MSI-H、TMB-H或林奇综合征的患者死亡风险：危险比(HR)：0.29(95%CI：0.12，0.72)；p=0.008。医疗记录短语(“杰出的反应”)与上述内容一致。1名患者在治疗后14天内死亡，1名患者在死亡后30天内住进重症监护病房。15人进入临终关怀中心，其中4人在3天后死亡。这些出人意料的有利发现突显了医疗保健提供者-包括姑息治疗提供者-需要在生命接近尾声时对患者进行癌症治疗的知识指导。
Pembrolizumab confers minimal benefit to patients with pancreas cancer. We explored survival and patient treatment burden (for example, death within 14 days of therapy) in a subgroup with early pembrolizumab access. This multisite study examined consecutive pancreas/pembrolizumab-treated patients from 2004 through 2022. Median overall survival of > 4 months was to be deemed favorable. Patient treatment burden and medical record quotations are presented descriptively. Forty-one patients (median age 66 years; range: 36, 84) are included. Fifteen (37%) had dMMR, MSI-H, TMB-H, or Lynch syndrome; and 23 (56%) received concurrent therapy. The median overall survival was 7.2 months (95% confidence interval (CI): 5.2, 12.7 months); 29 were deceased. Patients with dMMR, MSI-H, TMB-H, or Lynch syndrome had a lower risk of death: hazard ratio (HR): 0.29 (95% CI: 0.12, 0.72); p=0.008. Medical record phrases (“brilliant response”) aligned with the above. One patient died within 14 days of therapy, and 1 was in an intensive care unit within 30 days of death. Fifteen enrolled in hospice, 4 of these died < 3 days later. These unexpectedly favorable findings underscore the need for healthcare providers – including palliative care providers – to knowledgeably guide patients about cancer therapy near the end-of-life.
登录
查看更多内容
影响因子：
50.3
作者：
Bear AS;Vonderheide RH;O'Hara MH
通讯作者：
O'Hara MH
影响因子：
8.4
作者：
Wang-Gillam, Andrea;Hubner, Richard A.;Chen, Li-Tzong
通讯作者：
Chen, Li-Tzong
影响因子：
10.9
作者：
Chakrabarti, Sakti;Bucheit, Leslie;Starr, Jason Scott;Innis-Shelton, Racquel;Shergill, Ardaman;Dada, Hiba;Resta, Regina;Wagner, Stephanie;Fei, Naomi;Kasi, Pashtoon Murtaza
通讯作者：
Kasi, Pashtoon Murtaza
影响因子：
3.6
作者：
Smith, Caleb J.;Bekaii-Saab, Tanios S.;Jatoi, Aminah
通讯作者：
Jatoi, Aminah
影响因子：
4.7
作者：
Duberstein PR;Chen M;Hoerger M;Epstein RM;Perry LM;Yilmaz S;Saeed F;Mohile SG;Norton SA
通讯作者：
Norton SA